Convalescent Plasma to Limit SARS-CoV-2 Associated Complications

PHASE2CompletedINTERVENTIONAL
Enrollment

1,225

Participants

Timeline

Start Date

June 3, 2020

Primary Completion Date

January 14, 2022

Study Completion Date

December 14, 2022

Conditions
SARS-CoV 2
Interventions
BIOLOGICAL

SARS-CoV-2 convalescent plasma

SARS-CoV-2 convalescent plasma (1 cup; minimum of 175 mL collected by apheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320 and after July 2021 meets FDA criteria for high titer plasma.

BIOLOGICAL

Plasma from a volunteer donor

Plasma collected from a volunteer donor prior to January 1, 2020 will not be tested for SARS-CoV-2 antibodies. Plasma collected after December 31, 2019 will be confirmed as SARS-CoV-2 seronegative.

Trial Locations (29)

12601

Vassar Brothers Medical Center, Poughkeepsie

14642

University of Rochester, Rochester

20782

MedStar Washington Hospital Center, Hyattsville

21205

The Johns Hopkins University, Baltimore

21401

Anne Arundel Medical Center, Annapolis

33124

University of Miami, Coral Gables

33136

University of Miami Clinical Translational Research Site, Miami

35294

University of Alabama at Birmingham, Birmingham

45219

University of Cincinnati Medical Center, Cincinnati

48202

Wayne State University, Detroit

60201

NorthShore University HealthSystem, Evanston

70112

Tulane University, New Orleans

77030

Baylor College of Medicine, Houston

University of Texas Health Science Center at Houston, Houston

84132

The University of Utah, Salt Lake City

85054

Mayo Clinic, Phoenix, Phoenix

85719

University of Arizona, Phoenix, Tucson

85724

University of Arizona, Tuscon, Tucson

85941

Center for American Indian Health - Whiteriver Office, Whiteriver

86503

Center for American Indian Health - Chinle Office, Chinle

87131

University of New Mexico Health Sciences Center, Albuquerque

87301

Center for American Indian Health - Gallup Office, Gallup

87420

Center for American Indian Health - Shiprock Office, Shiprock

90095

University of California, Los Angeles, Los Angeles

92868

University of California, Irvine Health, Orange

06810

Western Connecticut Health Network, Danbury Hospital, Danbury

06856

Western Connecticut Health Network, Norwalk Hospital, Norwalk

01655

University of Massachusetts Worcester, Worcester

02903

Lifespan/BrownUniversity (Rhode Island Hospital), Providence

All Listed Sponsors
collaborator

State of Maryland

OTHER_GOV

collaborator

Bloomberg Philanthropies

OTHER

collaborator

United States Department of Defense

FED

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

lead

Johns Hopkins University

OTHER

NCT04373460 - Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | Biotech Hunter | Biotech Hunter